Full-Time

Senior Director

Commercial Manufacturing & CMC Development

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$230k - $275kAnnually

+ Performance Bonus + Equity

Senior, Expert

San Francisco, CA, USA

This is a hybrid position, which implies that the candidate will be required to work in-office for part of the week.

Category
Biology Lab & Research
Biology & Biotech

You match the following BridgeBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 15+ years in the pharmaceutical industry, with a focus on small-molecule development, commercial manufacturing, and CMC leadership.
  • Deep understanding of API and DP manufacturing, GMP regulations, quality systems, and global supply chain management.
  • Demonstrated ability to lead multidisciplinary teams, manage complex projects, and influence strategic decision-making in a matrixed environment.
  • Direct experience with global regulatory filings, inspections, and compliance standards, including authoring and reviewing Module 3 documentation.
Responsibilities
  • Oversee end-to-end commercial manufacturing activities, including supplier selection, technology transfer, and ongoing process optimization for both drug substance and drug product.
  • Ensure GMP compliance, robust quality systems, and regulatory readiness to support commercial supply and global product launches.
  • Drive the CMC strategy from late-phase development through commercialization, collaborating with cross-functional teams (R&D, Quality, Regulatory, Supply Chain) to ensure seamless integration of manufacturing processes.
  • Lead and advise on CMC-related sections for regulatory submissions, ensuring alignment with international health authority expectations.
  • Manage relationships with CDMOs and raw material suppliers, negotiating contracts, setting performance standards, and overseeing quality and timelines.
  • Continuously evaluate the external network, identifying new partners and implementing improvements to enhance cost-effectiveness and supply reliability.
  • Build, mentor, and inspire a high-performing team of CMC professionals, fostering a culture of innovation, accountability, and continuous improvement.
  • Provide strategic guidance on talent development and resource planning to support evolving business needs.
  • Apply broad scientific knowledge of chemistry, process R&D, and manufacturing best practices to resolve technical challenges.
  • Guide process scale-up, technology transfers, and troubleshooting activities to ensure product consistency and on-target performance.
Desired Qualifications
  • Advanced degree in Chemistry, Chemical Engineering, Pharmaceutical Sciences, or a related field preferred.

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

5%

1 year growth

1%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off